A new animal study out of the Washington University School of Medicine indicates that disruptions in an individual’s sleep-wake cycle may be an early indicator of Alzheimer’s disease.
Scientists measured amyloid plaques, one of the defining brain abnormalities associated with Alzheimer’s disease, in mice that were genetically altered to develop these Alzheimer’s plaques as they age. Researchers found that when the first indicators of these plaques began to appear, mice began experiencing a change in their sleep patterns. Mice generally sleep 40 minutes during every hour of daylight, but when the plaques began forming the mice averaged just 30 minutes of sleep during every hour of daylight. In aging mice that did not develop Alzheimer’s plaques, no change in sleep patterns was observed.
“If sleep abnormalities begin this early in the course of human Alzheimer’s disease, those changes could provide us with an easily detectable sign of pathology,” says senior author David M. Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of Washington University’s Department of Neurology. “As we start to treat Alzheimer’s patients before the onset of dementia, the presence or absence of sleep problems may be a rapid indicator of whether the new treatments are succeeding.”
More research will be needed to establish a cause and effect relationship or prove this correlation in humans, but previous studies have found that amyloid levels and plaques behave similarly in both humans and mice.
Read more about the Alzheimer's disease study, including an audio overview of the findings.
All About Alzheimer’s: Slowing the Aging Process, Digital Health Apps, Sense of Smell as Alzheimer’s Indicator
Scientists have developed an experimental medication that aids in ameliorating the effects of Alzheimer’s disease by slowing down the aging process. T...
President Ronald Reagan designated November as National Alzheimer’s Awareness Month in 1983 – at a time in the United States when fewer than 2 million...
Health and Wellness, Medication Management, Medication Technology & Informatics, Memory Care Best Practices and Research
The University of North Carolina at Chapel Hill has been awarded a $3.4 million grant from the National Institute on Aging to study the use of antipsy...
End of Life, Medication Management, Memory Care Best Practices and Research
Total health spending for people with dementia was more than a quarter-million dollars per person during the last five years of life, which is approxi...
The Pan American Health Organization, which is the World Health Organization’s agency for the Americas, has adopted a regional plan of action on demen...
Facts and Figures, Health and Wellness, Medication Management, Memory Care Best Practices and Research, Memory Care Education, Reports
A large, national clinical trial to study the effect of resveratrol long-term in people with mild to moderate Alzheimer’s disease found that a biomark...
All About Alzheimer’s: Receptor Drug Success, Gene Signatures, Type 2 Diabetes, and Expanding Waistlines
There are currently five medications approved by the FDA to treat Alzheimer’s disease but these drugs mask the symptoms rather than stop the disease f...
End of Life, Engage, Managed Risk, Membership, Memory Care Best Practices and Research, Memory Care Education
The Alzheimer’s Foundation of America has announced that National Memory Screening Week will take place the first week of November and participating s...
Facts and Figures, Memory Care Best Practices and Research, Memory Care Education, Reports
There are currently about 46.8 million people around the globe living with dementia with those figures expected to nearly double every 20 years, find...
The Dementia Action Alliance has a released a new report outlining language use related to dementia, noting that these words currently used to describ...